LncRNA-MAFG-AS1在结直肠癌中的表达及临床意义

目的 探讨LncRNA-MAFG-AS1在结直肠癌中的表达及临床意义。方法 选取我院行手术切除的结直肠癌组织及对应的癌旁正常组织各80例,应用定量即时聚合酶链锁反应(quantitative real time polymerase chain reaction, qRT-PCR)检测结直肠癌组织及癌旁正常组织中LncRNA-MAFG-AS1的表达水平,并分析其与结直肠癌临床病理特征之间的关系,所有患者随访截止日期到2019年12月31日,应用Kaplan-Meier(K-M)法进行生存分析,采用Cox回归模型分析结直肠癌预后的危险因素。结果 结直肠癌组织中LncRNA-MAFG-AS1相对表达量为2.398±0.214,高于癌旁正常组织的1.032±0.132,差异有统计学意义(P<0.05)。当患者TNM分期更高、中高分化及存在淋巴结转移和远期转移时,LncRNA-MAFG-AS1过表达(P<0.05)。K-M生存分析显示高表达患者无进展生存时间(progression-free survival, PFS)为(20.36±3.21)个月,低表达患者为(29.71±4....     

443例胃癌根治术后发生肺部并发症的危险因素

目的 探讨胃癌根治术术后肺部并发症(PPCs)的相关危险因素,为PPCs的个体化防治提供相应的对策。 方法 回顾性分析2019年1月至2021年3月兰州大学第二医院普通外科443例胃癌患者的临床资料,统计患者的临床病理特征,采用二分类Logistic回归分析胃癌根治术PPCs的危险因素。 结果 443例胃癌根治术PPCs的发生率为18.1%(80/443),其中肺部感染的发生率为12.4%(55/443),胸腔积液的发生率为11.7%(52/443),发生PPCs较未发生PPCs住院时间延长。Logistic回归分析显示,年龄≥60岁(OR=0.424、95%CI: 0.241~0.746)、糖尿病史(OR=0.318、95%CI: 0.146~0.693)、每分钟最大通气量(MVV)(%)<85%(OR=0.509、95%CI: 0.297~0.874)、术中失血量≥200 mL(OR=0.496、95%CI: 0.276~0.797)和术后吻合口并发症(OR=4.038、95%CI: 1.250~13.049)是胃癌根治术发生PPCs的独立危险因素。 结论 对于年龄≥60岁、糖尿病史、MVV(%)<85%、术中失血量≥200 mL、术后吻合口并发症的胃癌患者,应注意预防PPCs的发生。     

经皮射频消融与手术切除治疗直径≤ 3 cm原发性小肝癌的疗效分析

目的 分析经皮射频消融（PRFA）与手术切除治疗直径≤3 cm原发性小肝癌的疗效。方法 选取2015年1月—2017年6月兰州市第二人民医院收治的原发性小肝癌患者78例。将36例接受PRFA治疗的患者作为观察组,另外42例行手术切除的患者作为对照组。采用全自动生化分析仪检测血清谷草转氨酶（AST）、谷丙转氨酶（ALT）、总胆红素（TBIL）水平,电化学发光全自动免疫分析仪检测血清甲胎蛋白（AFP）水平。结果 观察组手术时间、术中出血量、住院时间均少于对照组（P <0.05）;观察组治疗前后AST、ALT、TBIL、AFP的差值均高于对照组组（P <0.05）。两组术后并发症比较,差异无统计学意义（P>0.05）;两组治疗后1、2、3、5年的生存率和复发率比较,差异均无统计学意义（P>0.05）。结论 与手术切除比较,PRFA治疗直径≤3 cm原发性小肝癌可缩短手术时间,减少术中出血量,促进肝功能恢复,但两者术后并发症发生率、生存率和复发率接近。     

老年腹股沟疝患者疝环充填式无张力修补术86例

目的总结弛环充填式无张力修补术治疗老年腹股沟疝患者的经验。方法回顾分析2002年3月-2005年7月采用德国Braun公司生产的Braun mesh和plug治疗的86例老年腹股沟疝患者的临床资料。结果平均手术时间35min，术后8-10h下床活动，2周恢复日常生活，伤口均一期愈合，术后尿潴留15例，异物感3例，随访3—40个月无一例复发。结论疝环充填式无张力修补术操作方便，创伤小，恢复快，复发率低，是老年患者理想有效的疝修补术。     

医源性血管损伤的预防和术中处理

目的：总结手术中发生医源性血管损伤的处理经验。方法：10例在外科手术中损伤血管的患者,其中门静脉,下腔静脉、髂总静脉损伤各2例,股总静脉、颈总动脉、腋静脉、腘动脉损伤各1例。行血管修补术5例,行端-端吻合术1例,自体静脉移植术1例,人工血管移植1例,钳夹止血1例,血管结扎1例。结果：本组痊愈8例;死亡2例,其中下腔静脉损伤止血失败死亡1例,颈总动脉损伤结扎死亡1例。结论：医源性血管损伤重在预防,一旦发生血管损伤,迅速有效地控制出血是手术成功的关键,血管修补或吻合术疗效良好。     

人体肠道生物力学特性的研究

为探讨人体肠道的生物力学特性，采用电子拉伸机对人体肠道进行一维拉伸试验。结果表明，人体肠道应力-应变关系为指数函数关系。人体肠道各段的指数系数a值接近，但材料常数C有一定的差异，说明肠道各段应力-应变趋势是一致的。在一定应力下，肠道各段轴向与环向的相对伸长率是不同的，表明人体肠道具有各向异性的特性。在一定应变下，肠道各段的增量弹性模量不同，结肠增量弹性模量相对较小，因而更容易发生变形。本研究为肠道内窥镜机器人的研制提供了理论基础。     

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans

BackgroundCryptococcus neoformans infections occur in immunocompromised patients, especially those with HIV infection, chemoradiotherapy after cancer, and organ transplantation. Infection can cause pneumonia and meningoencephalitis in severe cases with a high mortality rate if not treated. Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of fluconazole resistance has increased significantly due to long-term use. Minocycline is a derivative of tetracycline that exerts its antibacterial effect through inhibition of bacterial protein synthesis. It is also able to pass the blood-brain barrier to act on the central nervous system. The present study investigates the effects of minocycline in combination with antifungals in treating C. neoformans.ObjectiveTo determine in vitro interactions of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole and amphotericin B against C. neoformans.MethodsThe minimum inhibitory concentrations (MIC) of the antifungals were determined by the CLSI Clinical and Laboratory Standards Institute M27-A3 microdilution method. The in vitro synergistic effects of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole, and amphotericin B on C. neoformans were detected by the broth microdilution checkerboard technique and disk diffusion testing.Results and ConclusionThe working concentration ranges were 0.125–4 µg/mL for itraconazole, 0.03–0.125 µg/ml for voriconazole, 0.03–1 µg/ml for posaconazole, 0.25–16 µg/ml for fluconazole, and 0.125–2 µg/ml for amphotericin B. The synergistic rates of minocycline combinations against C. neoformans were 55% with itraconazole, 10% with voriconazole, 85% with posaconazole, 20% with fluconazole, and 70% with amphotericin B. The effective MIC value of minocycline in the synergistic combination decreased to 2–32 µg/ml, while the MIC of itraconazole decreased to 0.03–0.125 µg/ml, voriconazole 0.03–0.125 µg/ml, posaconazole 0.03–0.125 µg/ml, 0.125–4 µg/ml fluconazole, and 0.06–0.50 µg/ml amphotericin B. The disk diffusion assay showed that the plates containing minocycline and antifungal drugs produced inhibition zones with diameters larger than the single drug plates. Minocycline showed no antagonistic effect in the combinations. In conclusion, the combination of minocycline and azoles or amphotericin B has synergistic effects against C. neoformans in vitro.     

PLPP2: Potential therapeutic target of breast cancer in PLPP family

PLPPs (Phospholipid phosphatases) are widely expressed in different human tissues, regulate cell signal transduction, and are overexpressed in cancers such as gliomas, pancreatic adenocarcinoma, lung adenocarcinoma, and so on. As a member of the PLPP family, PLPP2 (phospholipid phosphatase 2) plays a vital role in the occurrence and development of breast cancer, but its mechanism is still unclear. Our research found that PLPP2 was overexpressed in breast cancer, and the higher expression level of PLPP2 showed a worse prognosis for breast cancer patients. Further analysis showed that overexpression of PLPP2 affected the expression of CDC34 (cell-division cycle 34), LSM7 (Like-Smith 7), and SGTA (small glutamine-rich tetratricopeptide repeat-containing protein alpha) through EMT (epigenetic-mesenchymal transition) related pathways to promote the occurrence and development of breast cancer. In vitro, silencing PLPP2 significantly reduced the proliferation, invasion, and migration abilities of human breast cancer cells MDA-MB-231. ER+ is a common subtype of breast cancer. Furthermore, we found that the overexpression of PLPP2 was significantly related to the poor prognosis of ER+ breast cancer. These results indicate that PLPP2 has value as a potential therapeutic target for breast cancer, especially for ER+ breast cancer.     

ZT胶作为门静脉栓塞材料的实验研究

目的探讨ZT胶行兔选择性门静脉栓塞（SPVE）的安全性及有效性。方法新西兰白兔24只，随机分为3组，A组为ZT胶：碘油（1：1）混合物组，B组为ZT胶：碘油（1：2）混合物组，对照组C组为碘油组。对各组门静脉左支进行SPVE，术后检测门静脉压力、肝转氨酶（ALT、AST）的变化，术后30d右肝重／全肝重、全肝重／体重。结果SPVE后门静脉压力、肝转氨酶呈一过性升高；栓塞后肝左叶萎缩、纤维化，肝右叶代偿性增生肥大．右肝重／全肝重B组为69．41％，而C组为39．00％。统计学分析显示，B组栓塞效果明显优于其他组（P〈0．05）。结论ZT胶：碘油（1：2）混合物是一种安全、有效的门静脉栓塞材料。     

人白介素- 4对牛血管内皮细胞保护作用的研究

目的:研究人白介素-4(hIL-4)对经TNF-α活化的牛主动脉内皮细胞(BAEC)的保护作用。方法:用不同浓度的hIL-4与BAEC共孵育2h后,再与4μg/L的TNF-α共孵育6h或18h。应用细胞ELISA方法,检测BAEC表面的E选择素和ICAM-1的表达;用MTT比色法测定hIL-4对BAEC活性的影响。结果:在一定浓度内用hIL-4预处理BAEC后,能明显抑制TNF-α诱导活化BAEC上的E选择素与ICAM-1的表达,并呈现一定的剂量依赖性。用MTT比色法测定BAEC活性的实验表明,各实验组BAEC的活性与对照组无明显差异性。结论:hIL-4能明显抑制TNF-α诱导活化的BAEC表达E选择素与ICAM-1;hIL-4对BAEC的正常功能具有一定的保护作用。